Cassady Schiller Wealth Management’s Blueprint Medicines BPMC Stock Holding History

Cassady Schiller Wealth Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	$698	Buy	+8	New	+$733	﹤0.01%	878

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Cassady Schiller Wealth Management's BPMC Position: Q4 2024 in Review

Cassady Schiller Wealth Management opened a new position in Blueprint Medicines (BPMC) in Q4 2024: 8 shares worth $698. The stake represents ﹤0.01% of the portfolio and ranks #878 among its holdings.

345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

Cassady Schiller Wealth Management held 8 shares of Blueprint Medicines worth $698 as of Q4 2024.
Blueprint Medicines was a new Cassady Schiller Wealth Management position in Q4 2024.
Blueprint Medicines made up ﹤0.01% of Cassady Schiller Wealth Management's portfolio in Q4 2024, its #878 holding.
345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q4 2024, filed 10 Feb 2025.